Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune response to Prevnar 13 in patients with recurrent infections with suboptimal response to PNEUMOVAX®23 who's clinical and laboratory presentation did not deem them eligible for IVIG:A retrospective review

Trial Profile

Immune response to Prevnar 13 in patients with recurrent infections with suboptimal response to PNEUMOVAX®23 who's clinical and laboratory presentation did not deem them eligible for IVIG:A retrospective review

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Pneumococcal vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 New trial record
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top